Andrew Bellinger

2021

In 2021, Andrew Bellinger earned a total compensation of $3.3M as Chief Scientific Officer at Verve Therapeutics, a 223% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$310,500
Option Awards$2,588,979
Salary$409,583
Other$7,117
Total$3,316,179

Bellinger received $2.6M in option awards, accounting for 78% of the total pay in 2021.

Bellinger also received $310.5K in non-equity incentive plan, $409.6K in salary and $7.1K in other compensation.

Rankings

In 2021, Andrew Bellinger's compensation ranked 4,034th out of 12,415 executives tracked by ExecPay. In other words, Bellinger earned more than 67.5% of executives.

ClassificationRankingPercentile
All
4,034
out of 12,415
68th
Division
Manufacturing
1,659
out of 5,505
70th
Major group
Chemicals And Allied Products
687
out of 2,375
71st
Industry group
Drugs
610
out of 2,096
71st
Industry
Pharmaceutical Preparations
428
out of 1,546
72nd
Source: SEC filing on April 29, 2022.

Bellinger's colleagues

We found two more compensation records of executives who worked with Andrew Bellinger at Verve Therapeutics in 2021.

2021

Sekar Kathiresan

Verve Therapeutics

Chief Executive Officer

2021

Allison Dorval

Verve Therapeutics

Chief Financial Officer

News

In-depth

You may also like